ClinicalTrials.gg
Active, not recruitingNCT03076034Updated Nov 10, 2026

Utility of Cortical Bone Tissue Properties in the Assessment of Fracture Risk

An interventional study of Reference Point Indentation in Distal Radius Fracture, Osteoporosis and Hip Fractures, sponsored by Beth Israel Deaconess Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 50 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Beth Israel Deaconess Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Jan 2015, registered Mar 2017).
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Non-randomized
Ages
50 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Wrist Fractures with a site in United States — 12 open to participants now, 19 under way, 1 of them phase 3. Wrist Fractures · United States.

Planned enrollment
8th of 64
190 · median 52
Started
2015
with 3 others
No phase
48 of 72
8 open now
Primary completion
2028-08
later than 16 of 18 live
Registered
29th of 72
by date
Lead sponsor
3 of 72
Beth Israel Deaconess Medical Center

Among the 72 studies in Wrist Fractures with a site in United States, this one is the 8th largest by planned enrollment of the 64 interventional ones that give a count, is one of 4 that started in 2015, is one of 48 with no phase, reaches primary completion later than 16 of the 18 other live ones, and was the 29th registered.

Wrist Fractures

331 studies on the registry are indexed under Wrist Fractures; 71 are open to participants now.

Browse Wrist Fractures studies →

Open to participants now

12 of the 72 studies in Wrist Fractures with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Wrist Fractures studies recruiting now, 20 (49%) set no upper age limit and 13 (32%) stop at 75 or younger; 7 take children under 18; 6 take healthy volunteers.

This study: 50 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Wrist Fractures with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to determine whether a new minimally invasive method for in vivo measurement of cortical bone tissue properties can identify those who are at risk for fragility fractures of the hip and radius. The investigators hypothesis is that women with fragility fractures of the hip and radius have altered cortical bone tissue properties compared to non-fracture controls independent of standard clinical tests, such as bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA).

Read the detailed description

The objective of this study is to determine whether a new minimally invasive method for in vivo measurement of cortical bone tissue properties can identify those who are at risk for fragility fractures of the hip and radius. The investigators hypothesis is that women with fragility fractures of the hip and radius have altered cortical bone tissue properties compared to non-fracture controls independent of standard clinical tests, such as BMD. To test these hypotheses, The investigators propose two aims:

Aim 1: Compare cortical bone tissue properties as assessed in vivo by reference point indentation in women with hip fractures and non-fracture controls.

The investigators will compare cortical bone tissue material properties, as assessed by novel in vivo indentation at the mid-tibia in postmenopausal women with recent hip fractures (n) and age-similar controls without fractures (n=). In addition to in vivo indentation measurements, The investigators will assess hip and spine BMD by DXA; as well as other factors that may influence risk of fractures (e.g, vit D status, medication use and physical activity). Hypotheses: Postmenopausal women with hip fractures will have worse bone tissue material properties compared to non-fracture controls even after adjustment for BMD and other potential confounders.

Aim 2: Compare cortical bone tissue properties as assessed in vivo by reference point indentation in women with distal radius fractures to non-fracture controls.

The investigators will compare cortical bone tissue material properties, as assessed by novel in vivo indentation at the mid-tibia in postmenopausal women with recent distal radius fractures (n) and age-similar controls without fractures (n=). In addition to in vivo indentation measurements, The investigators will assess hip and spine BMD by DXA; as well as other factors that may influence risk of fractures (e.g, vit D status, medication use and physical activity). Hypotheses: Postmenopausal women with distal radius fractures will have worse bone tissue material properties compared to non-fracture controls even after adjustment for BMD and other potential confounders.

Successful completion of this project will address the need to better assess bone mechanical properties at the tissue level in order to accurately predict fracture risk. The study will provide novel information about possible clinical utility of minimally invasive, in vivo bone indentation measurements to measure bone strength and its relationship to fracture risk.

Aim 3: An amendment to the protocol expanded the study population to now include males >50 years who present with distal radius fractures and those who present for a reason other than fracture (non-fracture controls). Hypotheses: Men >50 years with distal radius fractures will have worse bone tissue material properties compared to non-fracture controls even after adjustment for BMD and other potential confounders.

03

Conditions studied

  • Distal Radius Fracture
  • Osteoporosis
  • Hip Fractures
04

Who can participate

Ages eligible
50 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with hip and wrist fractures within 2 weeks of presentation
  • Non-fracture controls

Exclusion criteria

Exclusion Criteria:

  • Unable to undergo BMD by DXA or high-resolution peripheral quantitative computed tomography (HR-pQCT)
  • History of skeletal , primary hyperparathyroidism, Paget's disease, multiple myeloma
  • Treatment with bisphosphonate, estrogen (within previous 3 years), teriparatide therapy, calcitonin, selective estrogen receptor modulator (SERMs,within previous 3 years)
  • Use of continuously for more than 3 months, use of anticonvulsants
  • Prior fracture in adulthood (>age 18) for healthy controls

Amendment to protocol added Arm 2, to include males >50 years with otherwise similar eligibility criteria.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    Post-menopausal women

    We will use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.

    Device: Reference Point Indentation

  • Experimental
    Males over 50 years

    We will recruit males to this second study arm, to use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.

    Device: Reference Point Indentation

Interventions

  • DeviceReference Point Indentation

    The "Osteoprobe": Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (\~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of \~375 µm.

    Also known as: Osteoprobe

06

What researchers measure

Primary outcomes

  1. Cortical bone tissue properties by reference point indentation

    Osteoprobe measurement

    Time frame: Day 1

  2. Bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA)

    DXA at the hip and spine

    Time frame: Day 1

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2015 (actual). Primary completion is estimated for Aug 2028, 162 months after the start.

Of 128 non-industry interventional studies with no phase under Wrist Fractures, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 162 months is above that.

Counting every sponsor, half of 129 studies reached it within 24 months; a quarter within 16 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Aug 2026 → Aug 2028 and completion Nov 2028 → Nov 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2017
First posted
Mar 9, 2017
StartActual
Jan 26, 2015
Primary completionEst.
Aug 8, 2028was Aug 2026
CompletionEst.
Nov 2030was Nov 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 8, 2026→Aug 8, 2028
Nov 10, 2026
Study completion
Nov 2028→Nov 2030
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Aug 8, 2026→Aug 8, 2028
    Study completion Nov 2028→Nov 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03076034
Responsible party
Tamara Rozental (Associate Professor, Harvard Medical School, Beth Israel Deaconess Medical Center) — Principal investigator
First posted
Mar 9, 2017
Start date
Jan 26, 2015
Primary completion
Aug 8, 2028 (estimated)
Completion
Nov 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Tamara Rozental, M.D.
principal investigator · Beth Israel Deaconess Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion